Avera Uses Pharmacogenomics, MEDITECH EHR to Drive Precision Medicine
Update: Since the original posting of this article on January 9, 2017, a press release has been issued with more details.
When a 2013 study suggested that pharmacogenomics could be used to improve the quality and safety of patient care, Avera Health — one of the largest health systems in the Midwest — set out to transform paper-oriented workflows at their human molecular genetics laboratory, the Avera Institute for Human Genetics.
Using the MEDITECH EHR, Avera’s clinical integration team implemented processes that incorporate pharmacogenomics into the clinical workflow, putting valuable genetic information in front of providers at the point of medication ordering.
This active clinical decision support enables providers to order the most effective pain medication for patients at the outset; this, in turn, supports floor nurses in their efforts to stay on top of managing patients’ pain.
"By leveraging the power and clinical sophistication of the MEDITECH EHR, Avera is transforming and improving the quality and safety of patient care," MEDITECH Associate Vice President of Marketing Christine Parent said in MEDITECH's press release. "We're proud to partner with this progressive healthcare organization in providing the actionable data needed to impact clinical decision making."
Learn how Avera converted pharmacogenomic results to actionable data that impacts clinical decision making. Download MEDITECH’s new case study, It’s in Their DNA: Avera Health Drives Precision Medicine at the Point of Care.